MX347503B - Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada. - Google Patents

Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.

Info

Publication number
MX347503B
MX347503B MX2013005047A MX2013005047A MX347503B MX 347503 B MX347503 B MX 347503B MX 2013005047 A MX2013005047 A MX 2013005047A MX 2013005047 A MX2013005047 A MX 2013005047A MX 347503 B MX347503 B MX 347503B
Authority
MX
Mexico
Prior art keywords
factor viii
specific activity
increased specific
new variant
antihemophilic factor
Prior art date
Application number
MX2013005047A
Other languages
English (en)
Other versions
MX2013005047A (es
Inventor
Kong Lai Chee
Kevin Stafford Roddy
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2013005047A publication Critical patent/MX2013005047A/es
Publication of MX347503B publication Critical patent/MX347503B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a el campo de terapia de hemofilia. Se refiere a una nueva variante del factor VIII antihemofílico que tiene actividad específica incrementada en comparación con productos conocidos del factor VIII.
MX2013005047A 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada. MX347503B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
MX2013005047A MX2013005047A (es) 2013-12-06
MX347503B true MX347503B (es) 2017-04-26

Family

ID=46025129

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015430A MX351220B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.
MX2013005047A MX347503B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016015430A MX351220B (es) 2010-11-05 2011-11-04 Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.

Country Status (18)

Country Link
US (2) US9150637B2 (es)
EP (1) EP2635297B1 (es)
JP (1) JP5922141B2 (es)
KR (1) KR101948337B1 (es)
CN (1) CN103298483B (es)
AU (1) AU2011323236B2 (es)
BR (1) BR112013011041B1 (es)
CA (1) CA2816575C (es)
CO (1) CO6720990A2 (es)
DK (1) DK2635297T3 (es)
EA (1) EA035447B1 (es)
ES (1) ES2721478T3 (es)
IL (1) IL226158B (es)
MX (2) MX351220B (es)
MY (1) MY165089A (es)
SG (2) SG10201509149VA (es)
WO (1) WO2012061689A2 (es)
ZA (1) ZA201303816B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250226B1 (en) 2015-01-30 2020-07-15 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
WO2017222330A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
DE69740154D1 (de) * 1996-04-24 2011-05-05 Univ Michigan Gegen Inaktivierung resistenter Faktor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU735763B2 (en) 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1194161B1 (en) 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1319016A4 (en) 2000-09-19 2006-05-10 Univ Emory MODIFIED FACTOR VIII
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
CN1630666A (zh) 2001-11-30 2005-06-22 埃默里大学 因子ⅷc2结构域变体
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
JP2007536230A (ja) 2004-05-03 2007-12-13 エモリー ユニバーシティ ブタＢドメイン欠損ｆＶＩＩＩの投与方法
SI3130601T1 (sl) * 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
US20090271163A1 (en) * 2007-12-06 2009-10-29 Wyeth Crystal structure of human factor VIII and uses thereof

Also Published As

Publication number Publication date
CN103298483B (zh) 2017-04-12
CA2816575A1 (en) 2012-05-10
SG190136A1 (en) 2013-07-31
EP2635297B1 (en) 2019-02-27
US9150637B2 (en) 2015-10-06
AU2011323236B2 (en) 2017-03-30
KR101948337B1 (ko) 2019-02-14
US10053500B2 (en) 2018-08-21
ES2721478T3 (es) 2019-07-31
EP2635297A4 (en) 2014-06-25
US20150353625A1 (en) 2015-12-10
IL226158A0 (en) 2013-06-27
CO6720990A2 (es) 2013-07-31
EA035447B1 (ru) 2020-06-17
AU2011323236A1 (en) 2013-06-06
ZA201303816B (en) 2021-05-26
JP2013545459A (ja) 2013-12-26
CA2816575C (en) 2019-06-11
JP5922141B2 (ja) 2016-05-24
DK2635297T3 (da) 2019-05-06
WO2012061689A3 (en) 2012-10-04
MX2013005047A (es) 2013-12-06
US20130296244A1 (en) 2013-11-07
SG10201509149VA (en) 2015-12-30
MX351220B (es) 2017-10-05
MY165089A (en) 2018-02-28
AU2011323236A8 (en) 2013-07-25
CN103298483A (zh) 2013-09-11
BR112013011041B1 (pt) 2021-05-25
BR112013011041A2 (pt) 2017-06-06
EA201390654A1 (ru) 2014-01-30
WO2012061689A2 (en) 2012-05-10
IL226158B (en) 2019-08-29
KR20140114266A (ko) 2014-09-26
EP2635297A2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
CA144362S (en) Combined dishwashing and scrubbing tool
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
UY34608A (es) Péptidos sintéticos de tránsito al cloroplasto.
ZA201206697B (en) Inverted dome to supply dose
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
IN2014DN09085A (es)
IN2014DN06104A (es)
BR112014014896A2 (pt) nova combinação
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
MX2015007727A (es) 6-cloro-3-(fenil-d5)inden-1-ona y su uso.
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
CY1117053T1 (el) Συνθεση μελιου με l-αλανυλ-l-γλουταμινη
MX347503B (es) Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
FR2969615B1 (fr) Nouveau complexes carbeniques de platine et leur utilisation comme medicaments
IN2015DN02647A (es)
MX2013002485A (es) Fenilacetamidas y fenilpropanamidas sustituidas y su uso.
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
AU338253S (en) Retail Unloader
AU336536S (en) Medical dressing
AU2010904081A0 (en) Delivery of Fabric Care Products
UA72478U (ru) Применение полентара как средства фригопротекторного действия
GB201015030D0 (en) Healing foot creme

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration